Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

49 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Osteoclast differentiation and activation.
Boyle WJ, Simonet WS, Lacey DL. Boyle WJ, et al. Among authors: simonet ws. Nature. 2003 May 15;423(6937):337-42. doi: 10.1038/nature01658. Nature. 2003. PMID: 12748652 Review.
Osteoprotegerin: a novel secreted protein involved in the regulation of bone density.
Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, L├╝thy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan HL, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, Hughes TM, Hill D, Pattison W, Campbell P, Sander S, Van G, Tarpley J, Derby P, Lee R, Boyle WJ. Simonet WS, et al. Cell. 1997 Apr 18;89(2):309-19. doi: 10.1016/s0092-8674(00)80209-3. Cell. 1997. PMID: 9108485
osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification.
Bucay N, Sarosi I, Dunstan CR, Morony S, Tarpley J, Capparelli C, Scully S, Tan HL, Xu W, Lacey DL, Boyle WJ, Simonet WS. Bucay N, et al. Among authors: simonet ws. Genes Dev. 1998 May 1;12(9):1260-8. doi: 10.1101/gad.12.9.1260. Genes Dev. 1998. PMID: 9573043 Free PMC article.
Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab.
Lacey DL, Boyle WJ, Simonet WS, Kostenuik PJ, Dougall WC, Sullivan JK, San Martin J, Dansey R. Lacey DL, et al. Among authors: simonet ws. Nat Rev Drug Discov. 2012 May;11(5):401-19. doi: 10.1038/nrd3705. Nat Rev Drug Discov. 2012. PMID: 22543469 Review.
Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis.
Min H, Morony S, Sarosi I, Dunstan CR, Capparelli C, Scully S, Van G, Kaufman S, Kostenuik PJ, Lacey DL, Boyle WJ, Simonet WS. Min H, et al. Among authors: simonet ws. J Exp Med. 2000 Aug 21;192(4):463-74. doi: 10.1084/jem.192.4.463. J Exp Med. 2000. PMID: 10952716 Free PMC article.
Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKL.
Kostenuik PJ, Nguyen HQ, McCabe J, Warmington KS, Kurahara C, Sun N, Chen C, Li L, Cattley RC, Van G, Scully S, Elliott R, Grisanti M, Morony S, Tan HL, Asuncion F, Li X, Ominsky MS, Stolina M, Dwyer D, Dougall WC, Hawkins N, Boyle WJ, Simonet WS, Sullivan JK. Kostenuik PJ, et al. Among authors: simonet ws. J Bone Miner Res. 2009 Feb;24(2):182-95. doi: 10.1359/jbmr.081112. J Bone Miner Res. 2009. PMID: 19016581
RANKL inhibition with osteoprotegerin increases bone strength by improving cortical and trabecular bone architecture in ovariectomized rats.
Ominsky MS, Li X, Asuncion FJ, Barrero M, Warmington KS, Dwyer D, Stolina M, Geng Z, Grisanti M, Tan HL, Corbin T, McCabe J, Simonet WS, Ke HZ, Kostenuik PJ. Ominsky MS, et al. Among authors: simonet ws. J Bone Miner Res. 2008 May;23(5):672-82. doi: 10.1359/jbmr.080109. J Bone Miner Res. 2008. PMID: 18433301
Expression of keratinocyte growth factor in embryonic liver of transgenic mice causes changes in epithelial growth and differentiation resulting in polycystic kidneys and other organ malformations.
Nguyen HQ, Danilenko DM, Bucay N, DeRose ML, Van GY, Thomason A, Simonet WS. Nguyen HQ, et al. Among authors: simonet ws. Oncogene. 1996 May 16;12(10):2109-19. Oncogene. 1996. PMID: 8668336
Pulmonary malformation in transgenic mice expressing human keratinocyte growth factor in the lung.
Simonet WS, DeRose ML, Bucay N, Nguyen HQ, Wert SE, Zhou L, Ulich TR, Thomason A, Danilenko DM, Whitsett JA. Simonet WS, et al. Proc Natl Acad Sci U S A. 1995 Dec 19;92(26):12461-5. doi: 10.1073/pnas.92.26.12461. Proc Natl Acad Sci U S A. 1995. PMID: 8618921 Free PMC article.
Progressive increases in bone mass and bone strength in an ovariectomized rat model of osteoporosis after 26 weeks of treatment with a sclerostin antibody.
Li X, Niu QT, Warmington KS, Asuncion FJ, Dwyer D, Grisanti M, Han CY, Stolina M, Eschenberg MJ, Kostenuik PJ, Simonet WS, Ominsky MS, Ke HZ. Li X, et al. Among authors: simonet ws. Endocrinology. 2014 Dec;155(12):4785-97. doi: 10.1210/en.2013-1905. Epub 2014 Sep 26. Endocrinology. 2014. PMID: 25259718
49 results
Jump to page
Feedback